Payers

NICE has updated its guidelines on the management of type 2 diabetes, recommending wider use of SGLT2 inhibitors in those with or at high-risk of cardiovascular disease (CVD).

The health service will make the new treatment, inclisiran, available to 300,000 patients with high cholesterol and a history of cardiovascular disease over the next three years.

A panel of regulators overseeing the implementation of several big data projects within the EU medicines network has given details of real-world evidence integration pilots to be undertaken next year.

The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ interleukin-17A (IL-17A) inhibitor Cosentyx (secukinumab) for the treatment of children and young people with moderate-to-severe psoriasis.

Passed by cabinet in October last year, the policy is aimed at regulating the prices of pharmaceutical products with a view to putting an end to pricing malpractices by different players in the industry.

China will reform the pricing of medical services provided by public hospitals as part of its campaign to make healthcare more affordable.

International Reference Pricing sounds great on paper but would unfortunately harm older adults and individuals with a disability.

IQWiG, Germany’s health technology appraisal institute, has found that Novartis’s gene therapy Zolgensma offers no additional benefit compared with Biogen’s Spinraza for treating spinal muscular atrophy.

The decision follows the agreement of a “population-level commercial deal” between the NHS and Novartis to make Leqvio “available with a discount to its list price”, said NICE.

Leqvio costs nearly 2,000 pounds, or about $2,750, per 284-milligram pack, but NICE negotiated a deal for what NHS describes as an "affordable and cost-effective price".

Even if Medicare decides to pay, patients generally would be responsible for 20 percent plus the cost of required testing and imaging.

ZIN, the Dutch health technology appraisal institute, has slammed the pricing of another rare disease treatment.

Rydapt is the first and only licensed treatment for advanced SM in the UK and has been shown to provide therapeutic benefits to adults with the disease.

In the past two weeks, the U.S. Chamber of Commerce and the Pharmaceutical Care Management Association have filed lawsuits challenging the price transparency rule for health insurers.

Canada’s efforts to reduce pharmaceutical prices should not come at the cost of contributing our fair share to developing new treatment innovations, and should rely more on negotiations with manufacturers than regulation.